` Comparison: R7E1 vs NOVN - Alpha Spread

C
R7E1
vs
NOVN

Over the past 12 months, R7E1 has underperformed NOVN, delivering a return of 0% compared to the NOVN's +32% growth.

Start AI Comparison

Smart Verdict
AI-Powered

Not Sure Which Stock Wins?
Let AI Decide.
R7E1
NOVN
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Smart Verdict is Ready!
See Who Stands Out.
All the numbers, charts, and metrics summarized into one smart verdict.
Stocks Compared:
Show Comparison Results
Summarizing...
We need a little more time to summarize the results

Valuation Comparison

C
R7E1 Intrinsic Value
Not Available
NOVN Intrinsic Value
107.11 CHF
Overvaluation 18%
Intrinsic Value
Price
Company Last Price Intrinsic Value DCF Value Relative Value Wall St Target
C
Cybin Inc
F:R7E1
13 EUR
Novartis AG
SIX:NOVN
130.16 CHF
No Stocks Selected

Compare the stock's valuation with its competitors.

Select Stocks to Compare
Valuation Scenario:
Bear Case
Base Case
Bull Case

Growth Comparison

Growth Over Time
R7E1, NOVN

R7E1
NOVN
Add Stock
Revenue
www.alphaspread.com
No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare
Company LTM Historical Growth Growth Streak % Positive Years Max Drawdown Volatility Forecasted Growth
3 Years 5 Years 10 Years 1 Year 3 Years
C
Cybin Inc
Revenue
Novartis AG
Revenue

All metrics are calculated based on data from the last 10 years.

No Stocks Selected

Compare company's financials with its competitors.

Select Stocks to Compare

Profitability Comparison

Free Cash Flow
R7E1, NOVN

R7E1
NOVN
Add Stock
Free Cash Flow
www.alphaspread.com
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
Company LTM Average Historical Growth FCF Margin Conversion
3 Years 5 Years 3 Years 5 Years 10 Years
C
Cybin Inc
F:R7E1
Novartis AG
SIX:NOVN
No Stocks Selected

Compare company's free cash flow with its competitors.

Select Stocks to Compare
What is Free Cash Flow?

Gross Margin

R7E1
0%
NOVN
75.8%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

Operating Margin

R7E1
0%
NOVN
33.2%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

Net Margin

R7E1
0%
NOVN
24.8%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

FCF Margin

R7E1
0%
NOVN
27.1%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

ROE

R7E1
-51.2%
NOVN
31%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

ROA

R7E1
-48.4%
NOVN
13.1%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

ROIC

R7E1
-140.1%
NOVN
17.8%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

ROCE

R7E1
-49.8%
NOVN
23.8%
LTM 3Y Avg 5Y Avg 10Y Avg
C
Cybin Inc
Novartis AG

Solvency Comparison

No Stocks Selected

Compare company's equity waterfall with its competitors.

Select Stocks to Compare
Balance Sheet Comparison
No Stocks Selected

Compare company's balance sheet with its competitors.

Select Stocks to Compare

Stocks Performance

Stocks Performance
R7E1, NOVN

Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
R7E1, NOVN

Loading
R7E1
NOVN
Difference
www.alphaspread.com

Performance By Year
R7E1, NOVN

Loading
R7E1
NOVN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Not Sure Which Stock Wins?
Let AI Decide
One-click summary across all key metrics.
Ranked results with clear takeaways.
No spreadsheets, no guesswork.
Start AI Comparison
Compare R7E1 to other stocks
LLY
Eli Lilly and Co
Cheaper
vs R7E1
JNJ
Johnson & Johnson
Cheaper
vs R7E1
ROG
Roche Holding AG
Cheaper
vs R7E1
AZN
AstraZeneca PLC
Cheaper
vs R7E1
Unlock Full Access to Alpha Spread
Create Free Account
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett